+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Peptichemio in pretreated patients with ovarian cancer

Cancer Treatment Reports 69(1): 17-20
Peptichemio in pretreated patients with ovarian cancer
From January 1978 to October 1982, 47 patients with histological diagnosis of epithelial cancer of the ovary received peptichemio (PTC) at a dose of 70 mg/m2 (maximum, 120 mg total) every 15 days. Forty-two patients are now evaluable: 27 with stage III and 15 with stage IV disease. All patients but four with stage IV disease had been pretreated and had received at least one drug combination (median, three drugs per patient, including alkylating agents). Before the administration of PTC, the tumor extension in the abdomen was carefully assessed in all patients: ten patients had residual tumor less than 2 cm in diameter, while 32 patients had tumor greater than 2 cm in diameter. Objective responses were obtained in ten patients (23.8%): six complete remissions and one partial remission were observed in stage III patients and one complete remission and two partial remissions were observed in stage IV patients. Of the ten responding patients, eight had tumors less than 2 cm in diameter before receiving PTC. The median duration of response was 16 months. The most frequent side effects were myelosuppression and phlebosclerosis. Bone marrow depression was a common finding after the third course in heavily pretreated patients. Accordingly, in these patients a schedule interval of 3 weeks should be more appropriate. Since most of the responders were in the "small tumor" category, PTC appears to be an active drug in patients with ovarian cancer having small tumors (less than 2 cm). On the other hand, the response rate in a nonselected population of patients remains to be clearly defined with further studies.

(PDF 0-2 workdays service: $29.90)

Accession: 006079561

PMID: 3155650

Related references

Peptichemio in pretreated patients with plasmacell neoplasms. European Journal of Cancer & Clinical Oncology 22(9): 1053-1058, 1986

Phase I study with weekly paclitaxel infusion in heavily pretreated advanced breast cancer and ovarian cancer patients. Onkologie 18(SUPPL 2): 100, 1995

Epirubicin + paclitaxel in pretreated advanced ovarian cancer patients. European Journal of Cancer 35(SUPPL 4): S243, Sept, 1999

High dose peptichemio in pretreated neuroblastoma. Anticancer Research 9(4): 1157-1160, 1989

Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. Journal of Cancer Research and Clinical Oncology 135(6): 815-821, 2008

Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. European Journal of Gynaecological Oncology 24(2): 169-170, 2003

Taxol in heavily pretreated patients with advanced breast and ovarian cancer. Onkologie 18(SUPPL 2): 100, 1995

Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients. International Journal of Gynecological Cancer 19(3): 455-459, 2009

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecologic Oncology 107(2): 326-330, 2007

Topotecan therapy as salvage in heavily pretreated ovarian cancer patients (hpocp). Journal of Clinical Oncology 24(18_suppl): 15057-15057, 2016